13 results on '"Saadat S"'
Search Results
2. Association between COVID-19 vaccination and stroke: a nationwide case-control study in Qatar.
- Author
-
Chemaitelly H, Akhtar N, Jerdi SA, Kamran S, Joseph S, Morgan D, Uy R, Abid FB, Al-Khal A, Bertollini R, Abou-Samra AB, Butt AA, and Abu-Raddad LJ
- Subjects
- Humans, Qatar epidemiology, Case-Control Studies, Male, Female, Middle Aged, Aged, Adult, BNT162 Vaccine administration & dosage, Odds Ratio, 2019-nCoV Vaccine mRNA-1273, Risk Factors, COVID-19 prevention & control, COVID-19 epidemiology, Stroke epidemiology, Vaccination adverse effects, COVID-19 Vaccines adverse effects, COVID-19 Vaccines administration & dosage, SARS-CoV-2
- Abstract
Objective: This study investigated the association between Coronavirus Disease 2019 mRNA vaccination and stroke in Qatar., Methods: Between December 1, 2020, and April 11, 2023, a matched case-control study was conducted to investigate the association between 3036 acute stroke cases and 3036 controls drawn from the entire population of Qatar., Results: The adjusted odds ratio (aOR) for vaccination among cases compared to controls was 0.87 (95% CI: 0.75-1.00). The aOR was 0.74 (95% CI: 0.45-1.23) for a single vaccine dose, 0.87 (95% CI: 0.73-1.04) for primary-series vaccination (two doses), and 0.91 (95% CI: 0.66-1.25) for booster vaccination (three or more doses). The aOR was 0.87 (95% CI: 0.72-1.04) for BNT162b2 and 0.86 (95% CI: 0.67-1.11) for mRNA-1273. Subgroup analyses, considering different durations since vaccination, also demonstrated no association. Subgroup analyses based on nationality, age, number of coexisting conditions, or prior infection status yielded similar results. Subgroup analysis, stratified by stroke type, suggested an association between vaccination and cerebral venous sinus thrombosis (aOR of 2.50 [95% CI: 0.97-6.44]), but it did not reach statistical significance., Conclusion: There was no evidence of an increased risk of stroke following vaccination, both in the short term and in the long term, extending beyond a year after receiving the vaccine., Competing Interests: Declarations of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no conflict of interest., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Oral cancer awareness and education within the pharmacy profession.
- Author
-
Saadat S, Longridge N, Shaw R, Walker A, and McCarthy C
- Subjects
- Humans, Male, Female, Cross-Sectional Studies, Pandemics, Dentists, Professional Role, Pharmacists, Surveys and Questionnaires, Attitude of Health Personnel, Pharmacies, COVID-19, Community Pharmacy Services, Mouth Neoplasms diagnosis, Pharmacy
- Abstract
The incidence of oral cancers are rising in the UK, with early detection a significant positive prognostic factor. The Covid-19 pandemic has negatively impacted patients access to dental services, reducing a potential avenue to diagnosis. Community pharmacists are well positioned to play an expanded role in supporting earlier detection. This study seeks to identify levels of awareness and knowledge of oral cancer amongst community pharmacists, to inform development of educational resources.A cross-sectional digital survey was distributed via social media between August and September 2021. Data were collected on participant's demographics, oral cancer awareness and educational resources relevant to oral cancer. The results obtained were analysed using descriptive statistics in IBM SPSS software.61 pharmacists completed the survey. The majority were female (n = 40; 65.6%) aged 18-30 (n = 33; 54.1%). Less than half of respondents reported feeling confident in recognising risk factors (37.7%; n = 23). A substantial minority (n = 8; 13.1%) incorrectly selected fluoride toothpaste use as a risk factor for oral cancer. Most respondents correctly suggested signposting patients with signs or symptoms of oral cancer to a General Medical or General Dental Practitioner (GDP) (n = 35; 57.3%, n = 46; 75.4%). 91.8% of respondents (n = 56) would welcome an educational resource to support professional development.This study demonstrates a need for further educational resources regarding oral cancer, specifically aimed at community pharmacists. Community Pharmacists have a crucial role in efforts to improve rates of early detection of oral cancers. Work should be completed to explore the establishment of direct referral pathways from community pharmacy to secondary care.
- Published
- 2023
- Full Text
- View/download PDF
4. Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection.
- Author
-
Sajadi MM, Myers A, Logue J, Saadat S, Shokatpour N, Quinn J, Newman M, Deming M, Rikhtegaran Tehrani Z, Magder LS, Karimi M, Abbasi A, Shlyak M, Baracco L, Frieman MB, Crotty S, and Harris AD
- Subjects
- Humans, Reinfection, Vaccination, Antibodies, Viral, COVID-19 Vaccines, Immunoglobulin A, Immunoglobulin G, SARS-CoV-2, COVID-19 prevention & control
- Abstract
With much of the world infected with or vaccinated against severe acute respiratory syndrome coronavirus 2 (commonly abbreviated SARS-CoV-2; abbreviated here SARS2), understanding the immune responses to the SARS2 spike (S) protein in different situations is crucial to controlling the pandemic. We studied the clinical, systemic, mucosal, and cellular responses to two doses of SARS2 mRNA vaccines in 62 individuals with and without prior SARS2 infection that were divided into three groups based on antibody serostatus prior to vaccination and/or degree of disease symptoms among those with prior SARS2 infection: antibody negative (naive), low symptomatic, and symptomatic. Antibody negative were subjects who were antibody negative (i.e., those with no prior infection). Low symptomatic subjects were those who were antibody negative and had minimal or no symptoms at time of SARS2 infection. Symptomatic subjects were those who were antibody positive and symptomatic at time of SARS2 infection. All three groups were then studied when they received their SARS2 mRNA vaccines. In the previously SARS2-infected (based on antibody test) low symptomatic and symptomatic groups, reactogenic symptoms related to a recall response were elicited after the first vaccination. Anti-S trimer IgA and IgG titers, and neutralizing antibody titers, peaked after the 1st vaccination in the previously SARS2-infected groups and were significantly higher than for the SARS2 antibody-negative group in the plasma and nasal samples at most time points. Nasal and plasma IgA antibody responses were significantly higher in the low symptomatic group than in the symptomatic group at most time points. After the first vaccination, differences in cellular immunity were not evident between groups, but the activation-induced cell marker (AIM
+ ) CD4+ cell response correlated with durability of IgG humoral immunity against the SARS2 S protein. In those SARS2-infected subjects, severity of infection dictated plasma and nasal IgA responses in primary infection as well as response to vaccination (peak responses and durability), which could have implications for continued protection against reinfection. Lingering differences between the SARS2-infected and SARS2-naive up to 10 months postvaccination could explain the decreased reinfection rates in the SARS2-infected vaccinees recently reported and suggests that additional strategies (such as boosting of the SARS2-naive vaccinees) are needed to narrow the differences observed between these groups. IMPORTANCE This study on SARS2 vaccination in those with and without previous exposure to the virus demonstrates that severity of infection dictates IgA responses in primary infection as well as response to vaccination (peak responses and durability), which could have implications for continued protection against reinfection.- Published
- 2022
- Full Text
- View/download PDF
5. Ischemic stroke in patients that recover from COVID-19: Comparisons to historical stroke prior to COVID-19 or stroke in patients with active COVID-19 infection.
- Author
-
Akhtar N, Abid F, Singh R, Kamran S, Imam Y, Al-Jerdi S, Salamah S, Al Attar R, Yasir M, Shabir H, Morgan D, Joseph S, AlMaslamani M, and Shuaib A
- Subjects
- Humans, Pandemics, Treatment Outcome, Brain Ischemia epidemiology, COVID-19 complications, COVID-19 epidemiology, Ischemic Stroke complications, Ischemic Stroke epidemiology, Stroke complications, Stroke diagnosis, Stroke epidemiology
- Abstract
Background and Purpose: Understanding the relationship of COVID-19 to stroke is important. We compare characteristics of pre-pandemic historical stroke (Pre-C), cases in acute COVID infection (Active-C) and in patients who have recovered from COVID-19 infection (Post-C)., Methods: We interrogated the Qatar stroke database for all stroke admissions between Jan 2019 and Feb 2020 (Pre-C) to Active-C (Feb2020-Feb2021) and Post-C to determine how COVID-19 affected ischemic stroke sub-types, clinical course, and outcomes prior to, during and post-pandemic peak. We used the modified Rankin Scale (mRS) to measure outcome at 90-days (mRS 0-2 good recovery and mRS 3-6 as poor recovery). For the current analysis, we compared the clinical features and prognosis in patients with confirmed acute ischemic stroke., Results: There were 1413 cases admitted (pre-pandemic: 1324, stroke in COVID-19: 46 and recovered COVID-19 stroke: 43). Patients with Active-C were significantly younger, had more severe symptoms, fever on presentation, more ICU admissions and poor stroke recovery at discharge when compared to Pre-C and Post-C. Large vessel disease and cardioembolic disease was significantly more frequent in Active-C compared to PRE-C or post-C., Conclusions: Stroke in Post-C has characteristics similar to Pre-C with no evidence of lasting effects of the virus on the short-term. However, Active-C is a more serious disease and tends to be more severe and have a poor prognosis., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
6. Characteristics and comparisons of acute stroke in "recovered" to "active COVID-19 and "pre-pandemic" in Qatar database.
- Author
-
Akhtar N, Abid F, Singh R, Kamran S, Imam Y, Al Jerdi S, Salameh S, Al Attar R, Yasir M, Shabir H, Morgan D, Joseph S, AlMaslamani M, and Shuaib A
- Subjects
- Humans, Pandemics, Qatar epidemiology, COVID-19 epidemiology, Ischemic Stroke diagnosis, Ischemic Stroke epidemiology, Stroke diagnosis, Stroke epidemiology
- Abstract
Understanding the relationship of COVID-19 to stroke is important. We compare characteristics of pre-pandemic stroke (PPS), cases in acute COVID infection (CS) and in patients who have recovered from COVID-19 infection (RCS). We interrogated the Qatar stroke database for all stroke admissions between Jan 2020 and Feb 2021 (PPS) to CS and RCS to determine how COVID-19 affected ischemic stroke sub-types, clinical course, and outcomes prior to, during and post-pandemic peak. There were 3264 cases admitted (pre-pandemic: 3111, stroke in COVID-19: 60 and recovered COVID-19 stroke: 93). Patients with CS were significantly younger, had more severe symptoms, fever on presentation, more ICU admissions and poor stroke recovery at discharge when compared to PPS and RCS. Large vessel disease and cardioembolic disease was significantly higher in CS compared to PPS or RCS. There was a significant decline in stroke mimics in CS. Stroke in RCS has characteristics similar to PPS with no evidence of lasting effects of the virus on the short-term. However, CS is a more serious disease and tends to be more severe and have a poor prognosis., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
7. Trends in stroke admissions before, during and post-peak of the COVID-19 pandemic: A one-year experience from the Qatar stroke database.
- Author
-
Akhtar N, Kamran S, Al-Jerdi S, Imam Y, Joseph S, Morgan D, Abokersh M, Uy RT, and Shuaib A
- Subjects
- Humans, Pandemics, Qatar epidemiology, Retrospective Studies, COVID-19 epidemiology, Ischemic Stroke, Stroke epidemiology
- Abstract
Background: Several reports document a decrease in the rates of stroke hospital admissions during the covid-19 pandemic. There is very little information whether the admission rates will change as the infection is controlled. We report on our rates of admissions before, during and following the peak of covid-19 infections in a prospective database from Qatar., Methods and Results: The stroke admissions in the six months prior to COVID-19 pandemic averaged 229/month. There was a decrease to 157/month in March-June during the peak of the pandemic. In the 6 months following the peak, as covid-19 numbers began to decrease, the average numbers increased back to 192/month. There was an increase in severe ischemic strokes and decreased in functional recovery. The decreased admissions were mainly driven by fewer stroke mimics. Patients presenting with ischemic stroke or cerebral hemorrhage remained unchanged., Conclusions: Fewer stroke mimics presenting to the hospital can explain the fewer admissions and poor outcome at the height of the covid-19 pandemic. The continued decrease in the number of ischemic stroke and stroke mimic admissions following the pandemic peak requires more study., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
8. The risk factors and related hospitalizations for cases with positive and negative COVID-19 tests: A case-control study.
- Author
-
Ghanei M, Keyvani H, Haghdoost A, Abolghasemi H, Janbabaei G, Reza Jamshidi H, Hosein Ghazale A, Hassan Saadat S, Gholami Fesharaki M, and Raei M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, COVID-19 mortality, COVID-19 therapy, Comorbidity, Female, Hospital Mortality, Humans, Iran, Male, Middle Aged, Predictive Value of Tests, Prognosis, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Young Adult, COVID-19 diagnosis, COVID-19 Testing, Hospitalization
- Abstract
Background: The aim of this study was to evaluate the risk factors for hospitalizations of cases with positive and negative COVID-19 tests., Methods: In this case-control study, the case and control groups consisted of 292 COVID-19 patients and 296 non-COVID-19 patients. Patients who referred to a reference laboratory in Tehran (Iran) in March 2020 were selected and interviewed. The patients were contacted by telephone and data were recorded through a questionnaire., Results: The sample of this study consisted of 588 patients (349 [59%] females, 239 [41%] males) with a mean age of 42 ± 15. The results of this study showed that comorbidities like diabetes (OR = 7.42), hypertension (OR = 4.85), asthma and respiratory diseases (OR = 5.64) in addition to symptoms including fever (OR = 6.67), chills (OR = 11.2), anorexia (OR = 11.3), dyspnea (OR = 4.8), weakness and lethargy (OR = 5.7) were the most predictive variables for hospitalization of non-COVID-19 cases. Furthermore, demographical variables like male gender (OR = 3.71), high age (>50; OR = 3.12), BMI (>25; OR = 2.37), travel (OR = 2.79), comorbidities including diabetes (OR = 5.26), hypertension (OR = 3.7) and underlying immunosuppressant patients receiving corticosteroid therapy (OR = 3.62) in addition to symptoms like anorexia [OR = 2.55] and dyspnea (OR = 6.99) tend to increase the risk of hospital admission in COVID-19 patients, suggesting their predictive values for hospitalization of COVID-19 patients., Conclusion: Our results indicated that different factors tend to increase the odds of hospital admission in patients with positive and negative COVID-19 tests, suggesting their predictive values for hospitalization., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
9. Effects of select dietary supplements on the prevention and treatment of viral respiratory tract infections: a systematic review of randomized controlled trials.
- Author
-
Shokri-Mashhadi N, Kazemi M, Saadat S, and Moradi S
- Subjects
- COVID-19 complications, COVID-19 epidemiology, Drugs, Chinese Herbal therapeutic use, Humans, Lactobacillus physiology, Panax chemistry, Quercetin therapeutic use, Randomized Controlled Trials as Topic statistics & numerical data, SARS-CoV-2 physiology, Vitamin D therapeutic use, Vitamin D Deficiency complications, Vitamin D Deficiency diet therapy, Vitamin D Deficiency epidemiology, beta-Glucans therapeutic use, COVID-19 prevention & control, COVID-19 therapy, Dietary Supplements classification, Respiratory Tract Infections epidemiology, Respiratory Tract Infections prevention & control, Respiratory Tract Infections therapy, Virus Diseases epidemiology, Virus Diseases prevention & control, Virus Diseases therapy
- Abstract
Introduction : Viral respiratory tract infections (RTIs) have been recognized as a global public health burden. Despite current theories about their effectiveness, the true benefits of dietary supplements on the prevention and treatment of viral RTIs remain elusive, due to contradictory reports. Hence, we aimed to evaluate the effectiveness of dietary supplements on the prevention and treatment of viral RTIs. Areas covered : We systematically searched databases of PubMed, Web of Science, Scopus, and Google Scholar through 4 March 2020, to identify randomized controlled trials that evaluated the effects of consuming selected dietary supplements on the prevention or treatment of viral RTIs. Expert opinion : Thirty-nine randomized controlled trials (n = 16,797 participants) were eligible and included. Namely, vitamin D supplementation appeared to improve viral RTIs across cohorts particulate in those with vitamin D deficiency. Among the evaluated dietary supplements, specific lactobacillus strains were used most commonly with selected prebiotics that showed potentially positive effects on the prevention and treatment of viral RTIs. Further, ginseng extract supplementation may effectively prevent viral RTIs as adjuvant therapy. However, longitudinal research is required to confirm these observations and address the optimal dose, duration, and safety of dietary supplements being publicly recommended.
- Published
- 2021
- Full Text
- View/download PDF
10. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.
- Author
-
Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, and Sajadi MM
- Subjects
- Adult, Aged, Asymptomatic Infections, COVID-19 Vaccines administration & dosage, Female, Humans, Immunoglobulin G blood, Male, Middle Aged, Vaccines, Synthetic administration & dosage, mRNA Vaccines, Antibodies, Neutralizing blood, Antibodies, Viral blood, COVID-19 immunology, COVID-19 Vaccines immunology, Health Personnel, SARS-CoV-2 immunology, Vaccines, Synthetic immunology
- Published
- 2021
- Full Text
- View/download PDF
11. Characteristics and Comparison of 32 COVID-19 and Non-COVID-19 Ischemic Strokes and Historical Stroke Patients.
- Author
-
Akhtar N, Abid FB, Kamran S, Singh R, Imam Y, AlJerdi S, AlMaslamani M, and Shuaib A
- Subjects
- Adult, Aged, Brain Ischemia diagnosis, Brain Ischemia therapy, COVID-19 diagnosis, COVID-19 therapy, Databases, Factual, Female, Humans, Male, Middle Aged, Patient Admission, Prognosis, Qatar, Risk Factors, Severity of Illness Index, Stroke diagnosis, Stroke therapy, Time Factors, Brain Ischemia etiology, COVID-19 complications, Stroke etiology
- Abstract
Objectives: The presence of COVID-19 infection may increase the risk of thrombotic events including ischemic strokes. Whilst a number of recent reports suggest that COVID-19 associated stroke tends to be severe, there is limited data on the effects of COVID-19 in prospective registries., Material and Methods: To determine how COVID-19 infection may affect cerebrovascular disease, we evaluated the ischemic stroke sub-types, clinical course and outcomes prior to and during the pandemic in Qatar. The Hamad General Hospital (HGH) stroke database was interrogated for stroke admissions during the last 4 months of 2019 and January-May 2020., Results: In Qatar the number of confirmed cases of COVID-19 increased from only 2 in February to 779 in March, 12,628 in April and 45,501 in May. Stroke admissions to HGH declined marginally from an average of 97/month for six pre-COVID months to 72/month in March-May. There were 32 strokes that were positive for COVID-19. When compared to non-COVID-19 stroke during the three months of the pandemic, COVID-19 patients were younger with significantly lower rates of hypertension, diabetes and dyslipidemia. COVID-19 positive patients had more cortical strokes (34.4% vs 5.6%; p = 0.001), severe disease (NIHSS >10: 34.4% vs 16.7%; p = 0.001) prolonged hospitalization and fewer with good recovery (mRS 0-2: 28.1% vs 51.9%; p = 0.001)., Conclusions: When compared to six pre-COVID-19 months, the number of ischemic stroke admissions during the three months of the pandemic declined marginally. COVID-19 positive patients were more likely to have a large cortical stroke with severe symptoms and poor outcome., Competing Interests: Declaration of Competing Interests None, (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
12. Early manifestation of ARDS in COVID-19 infection in a 51- year-old man affected by Mounier-Kuhn Syndrome
- Author
-
Morteza Izadi, Fatemeh Dehghanpoor, Babak Otoukesh, Behzad Einollahi, Ramezan Jafari, Seyed Hassan Saadat, Luca Cegolon, Mohammad Javanbakht, Jafari, R., Cegolon, L., Dehghanpoor, F., Javanbakht, M., Izadi, M., Saadat, S. H., Otoukesh, B., and Einollahi, B.
- Subjects
Male ,ARDS ,Computed tomography ,030204 cardiovascular system & hematology ,Critical Care and Intensive Care Medicine ,0302 clinical medicine ,Medicine ,Viral ,Respiratory system ,Tomography ,Lung ,Respiratory Distress Syndrome ,Respiratory tract infections ,medicine.diagnostic_test ,Middle Aged ,X-Ray Computed ,Mounier-Kuhn syndrome,Lung ,Trachea ,Radiology ,Cardiology and Cardiovascular Medicine ,Coronavirus Infections ,Human ,Pulmonary and Respiratory Medicine ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Respiratory tract infection ,Coronavirus disease 2019 (COVID-19) ,Pneumonia, Viral ,Article ,03 medical and health sciences ,COIVD-19 ,Mounier-Kuhn syndrome ,COVID-19 ,Dyspnea ,Humans ,Pandemics ,Tomography, X-Ray Computed ,Tracheobronchomegaly ,Bronchiectasis ,Pandemic ,Coronavirus Infection ,business.industry ,urogenital system ,Pneumonia ,medicine.disease ,030228 respiratory system ,business - Abstract
A 51-year-old man known to be affected by Mounier-Kuhn syndrome (MKS). presented to Accident & Emergecy (A&E) with fever, dyspnea and deterioration of his chronic coughs. Increased diameters of his trachea (39 mm), right (30 mm) and left (26 mm) main bronchi were revealed by chest computerized tomography (CT) scan. CT scan showed also ground-glass opacities (GGO) and bronchiectasis in the mid and lower zones of both lungs. COIVD-19 infection was eventually confirmed by RT-PCR. A severe form of COVID-19 could occur even in the early stages of the disease in presence of underlying co-morbidities including MKS, which increases the susceptibility to more recurrent and severe respiratory infections.
- Published
- 2020
13. Large saddle pulmonary embolism in a woman infected by COVID-19 pneumonia
- Author
-
Atefeh Jafari, Seyed Hassan Saadat, Luca Cegolon, Ramezan Jafari, Babak Otoukesh, Morteza Izadi, Behzad Einollahi, Bahareh Heshmat Ghahderijani, Mandana Kashaki, Mohammad Javanbakht, Jafari, R., Cegolon, L., Jafari, A., Kashaki, M., Otoukesh, B., Ghahderijani, B. H., Izadi, M., Saadat, S. H., Einollahi, B., and Javanbakht, M.
- Subjects
2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Betacoronavirus ,Pandemic ,medicine ,Humans ,Viral ,COVID-19 ,Coronavirus Infections ,Female ,Middle Aged ,Pandemics ,Pulmonary Embolism ,SARS-CoV-2 ,biology ,Coronavirus Infection ,business.industry ,Pneumonia ,medicine.disease ,biology.organism_classification ,Virology ,Pulmonary embolism ,Cardiovascular Flashlight ,Cardiology and Cardiovascular Medicine ,business ,Human - Abstract
n/a
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.